Evidence map›Paper›PMID 34745083›Full record

ArticleFrontiers in immunology2021

Mitochondrial Fission Factor Is a Novel Interacting Protein of the Critical B Cell Survival Regulator TRAF3 in B Lymphocytes.

Yingying Liu, Samantha Gokhale, Jaeyong Jung, Sining Zhu, Chang Luo, Debanjan Saha, Jessie Yanxiang Guo, Huaye Zhang, Saw Kyin, Wei-Xing Zong and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Multifaceted roles of mitochondria in asthma.Cell biology and toxicology · 2024
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yingying LiuDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, United States.
Samantha GokhaleDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, United States.
Jaeyong JungDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, United States.
Sining ZhuDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, United States.
Chang LuoDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, United States.
Debanjan SahaDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, United States.
Jessie Yanxiang GuoRutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States.
Huaye ZhangDepartment of Neuroscience and Cell Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, United States.
Saw KyinDepartment of Molecular Biology, Princeton University, Princeton, NJ, United States.
Wei-Xing ZongRutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States.
Eileen WhiteRutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States.
Ping XieDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, United States.
Rutgers, The State University of New Jersey · USPrinceton University · USRutgers Cancer Institute of New Jersey

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI PANOS G. GEORGOPOULOS · 1988 to 2026
$47.4M
Protein and redox homeostasis in cancer development and therapyR01CA129536 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI ZONG, WEI-XING · 2008 to 2022
$4.8M
Glutamine synthetase in cancer cell metabolism and oncogenesisR01CA224550 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI Wei-Xing Zong · 2018 to 2026
$4.7M
PI3 kinase PIK3CB (p110beta) in membrane trafficking and metabolismR01CA232246 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI ZONG, WEI-XING · 2018 to 2022
$1.8M
Molecular mechanisms of B cell malignant transformationR01CA158402 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI XIE, PING · 2012 to 2016
$1.6M
NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA129536NCI NIH HHS R01 CA158402NCI NIH HHS R01 CA224550NCI NIH HHS R01 CA232246NIEHS NIH HHS P30 ES005022
6 · The paper itself

Abstract

Proteins controlling mitochondrial fission have been recognized as essential regulators of mitochondrial functions, mitochondrial quality control and cell apoptosis. In the present study, we identified the critical B cell survival regulator TRAF3 as a novel binding partner of the key mitochondrial fission factor, MFF, in B lymphocytes. Elicited by our unexpected finding that the majority of cytoplasmic TRAF3 proteins were localized at the mitochondria in resting splenic B cells after

Indexed as

AnimalsApoptosisB-LymphocytesCell Line, TumorCell RespirationCell SurvivalDynaminsHumansMembrane ProteinsMiceMitochondrial DynamicsMitochondrial ProteinsReactive Oxygen SpeciesTNF Receptor-Associated Factor 3DNM1L protein, humanDynaminsMembrane ProteinsMff protein, humanMitochondrial ProteinsReactive Oxygen SpeciesTNF Receptor-Associated Factor 3apoptosisB cell malignanciesB lymphocytesMFFmitochondriaTRAF3

Identifiers

PMID34745083
PMCPMC8564014
OpenAlexW3211421509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.